News | October 26, 2021
ANG Life Sciences India H1FY22 consolidated PAT zooms to Rs. 33.77 crore
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
ANG Lifesciences India Limited has reported financial results for the period ended September 30, 2021
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Collaboration designed to bring reproductive health screening capabilities to hospitals and clinics across the country
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Subscribe To Our Newsletter & Stay Updated
